Medexus Announces Strong Fiscal Q1 2024 Results, Including Record Quarterly Revenue of US$31.6 Million

Stock Information for Medexus Pharmaceuticals Inc Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medexus Pharmaceuticals Inc Ordinary Shares

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Medexus Schedules Third Fiscal Quarter 2025 Conference Call
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.